Advanced HCC: emerging molecular therapies

Area of Science:

• Hepatology and Oncology
• Molecular Biology and Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a major cause of cancer death globally, with rising incidence in Western countries.
• Chronic liver disease, Hepatitis C, and non-alcoholic steatohepatitis contribute to HCC development.
• Current HCC treatments, including surgery, ablation, and sorafenib, have limitations, especially for advanced stages.

Purpose of the Study:

• To review novel therapeutic agents for hepatocellular carcinoma (HCC) currently in Phase III clinical trials.
• To highlight emerging treatments targeting specific molecular alterations in liver cancer.
• To provide an overview of front-line, second-line, and other indications for investigational HCC therapies.

Main Methods:

• Literature review of ongoing Phase III clinical trials for HCC.
• Analysis of targeted therapies focusing on specific molecular pathways in liver cancer.
• Synthesis of data on agents for front-line, second-line, and other HCC treatment settings.

Main Results:

• Several novel molecularly targeted agents are progressing through Phase III studies for HCC.
• These agents aim to improve survival and treatment outcomes for various stages of liver cancer.
• The research landscape for HCC is dynamic, with a focus on personalized medicine approaches.

Conclusions:

• The development of targeted therapies represents a significant advancement in HCC treatment.
• Ongoing Phase III studies are crucial for evaluating the efficacy and safety of new HCC agents.
• Future HCC management will likely involve a combination of existing treatments and novel targeted therapies.